CardiaTec Biosciences
CardiaTec Biosciences is a Cambridge University spinout applying AI and multi-omics analysis of human heart tissue to discover novel cardiovascular drug targets for out-licensing to pharmaceutical and biotechnology partners.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What CardiaTec Biosciences does
CardiaTec Biosciences is a Cambridge-based, Cambridge University spinout digital biotechnology company founded in 2021–2022 that applies artificial intelligence and machine learning to cardiovascular drug discovery. The company's core product is a computational multi-omics platform that ingests and analyzes large-scale biological datasets — including genomics, proteomics, and metabolomics — derived from human heart tissue samples, with the goal of identifying novel therapeutic targets for cardiovascular disease. To feed this platform, CardiaTec has established data-acquisition collaborations with hospitals in the United States and United Kingdom, building what it describes as an extensive proprietary dataset from human cardiovascular tissue that is intended to function as a durable data advantage over generic AI-bio approaches.
The company's business model is structured as a B2B biotech platform: it discovers and validates novel cardiovascular therapeutic targets internally, with the intention of out-licensing or partnering those targets with larger pharmaceutical and biotechnology companies for downstream development and commercialization. Revenue mechanics, when they materialize, are expected to flow from licensing deals, milestone payments, and royalties — there are no published product prices, no named paying customers, and no disclosed commercial agreements at present. CardiaTec is a preclinical-stage venture and currently operates as a private, venture-backed company.
To date, CardiaTec has raised approximately £1.4 million in pre-seed funding (July 2022) and $6.5 million in seed funding (September 2024), for cumulative capital of roughly $8.2 million. The investor base spans Laidlaw Scholars Ventures, APEX Ventures, Montage Ventures, Continuum Health Ventures, Panacea Capital, O2h Ventures, Crista Galli Ventures, and University of Cambridge Enterprise. The company operates from Cambridge, UK, with a headcount of 11–50 employees and a development timeline of under two years from founding to seed close. Marketing and distribution occur through industry conferences, academic channels, and direct enterprise engagement with pharmaceutical partners rather than through conventional product-led channels.
CardiaTec Biosciences firmographics
Firmographics- Name
- CardiaTec Biosciences
- Website
- https://www.cardiatec.ai/
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CardiaTec Biosciences is a Cambridge University spinout applying AI and multi-omics analysis of human heart tissue to discover novel cardiovascular drug targets for out-licensing to pharmaceutical and biotechnology partners.
- Ownership category
- akta.pro rank
CardiaTec Biosciences industry classification
Industry- Product category
- AI-driven Cardiovascular Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where CardiaTec Biosciences is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
CardiaTec Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Drug Target Discovery & Licensing: The company discovers novel therapeutic targets for cardiovascular diseases through its computational platform. These targets can be out-licensed to pharmaceutical companies for further development and commercialization, generating milestone payments and royalties.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
CardiaTec Biosciences product offering
Product offeringCore offering
CardiaTec Biosciences operates a computational drug discovery platform that applies AI and machine learning to large-scale multi-omics data derived from human heart tissue to identify and validate novel therapeutic targets for cardiovascular disease. These targets are out-licensed or partnered with pharmaceutical and biotech companies for further development and commercialization.
Product overview
CardiaTec Biosciences operates a unified computational platform for multi-omics analysis focused on cardiovascular drug discovery. The platform processes large-scale biological data from human heart tissues to uncover novel therapeutic targets and advance AI-driven treatment development. The company collaborates with hospitals in the US and UK to obtain multiomic data for its analysis.
Differentiator
Problem solved
Functional benefit
Products and services
- Computational Multi-omics Drug Discovery Platform
Companies that use CardiaTec Biosciences
Customer profileSegments1 record
Ideal customer profiles1 record
CardiaTec Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
CardiaTec Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- US and UK HospitalscoreCollaborating with hospitals in the United States and United Kingdom to access human heart tissue samples for multi-omics data analysis. These partnerships provide the biological data necessary to build the company's proprietary cardiovascular database for drug discovery.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
CardiaTec Biosciences competitors and assessment
Company assessmentBroad incumbents
- Isomorphic Labs: Alphabet's AI drug discovery subsidiary applying deep learning to biology. Comparable AI-first drug discovery platform with strong computational biology capabilities, though backed by significantly greater resources and broader therapeutic scope.
- Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery platform combining high-throughput biology with machine learning across multiple therapeutic areas. Directly comparable to CardiaTec in applying AI/ML to biological data for novel target identification, though operating at much greater scale and across broader indications.
Direct peers
- Iambic Therapeutics: Iambic (formerly Entos) combines AI-driven platform chemistry with computational biology for drug discovery. Similar preclinical, platform-based AI discovery approach with target ID and lead generation capabilities aimed at pharma partnerships.
- Insitro: Insitro applies machine learning to large-scale biological data for drug discovery, with a similar platform model combining proprietary datasets and AI. Both companies leverage multi-omic and cellular data to identify therapeutic targets and partner with larger pharma for development.
- Exscientia: Exscientia (now operating under Recursion) was a pioneer in AI-driven drug design and target identification with pharma partnerships. Comparable platform-based AI discovery model focused on generating novel targets and candidates for out-licensing.
- BenevolentAI: BenevolentAI uses AI to mine biomedical knowledge and identify novel drug targets, with a similar target-discovery and partnership-based business model. Comparable in being a European-headquartered AI drug discovery platform pursuing licensing economics with pharma.
Emerging players
- Standigm: Standigm is an AI-driven drug discovery company applying proprietary AI workflows to identify novel targets and candidates. Comparable platform-based AI discovery approach aimed at pharma partnerships, though broader in therapeutic scope.
- Owkin: Owkin applies AI to biological and clinical data for drug discovery and development. Comparable in using AI to mine large biomedical datasets for novel therapeutic insights, with hospital and academic data partnerships similar to CardiaTec's tissue sourcing model.
- Tenaya Therapeutics: Tenaya is a clinical-stage biotech focused on cardiovascular disease therapeutics. Comparable through the cardiovascular therapeutic focus and reliance on advanced biological platforms to identify novel cardiac targets.
- Cardior Pharmaceuticals: Cardior is a European biotech focused on RNA-based therapeutics for cardiovascular disease. Comparable through dedicated cardiovascular therapeutic focus and use of advanced biological platforms, though focused on a different therapeutic modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
CardiaTec Biosciences social profiles
Digital presenceCardiaTec Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardiaTec Biosciences leadership team
Management profileNumber of profiles
Profiles1 record
CardiaTec Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardiaTec Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardiaTec Biosciences
What does CardiaTec Biosciences do?
CardiaTec Biosciences operates a computational drug discovery platform that applies AI and machine learning to large-scale multi-omics data derived from human heart tissue to identify and validate novel therapeutic targets for cardiovascular disease. These targets are out-licensed or partnered with pharmaceutical and biotech companies for further development and commercialization.
Is CardiaTec Biosciences a public or private company?
CardiaTec Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was CardiaTec Biosciences founded?
CardiaTec Biosciences was founded in 2021. It employs 11 to 50 people.
Where is CardiaTec Biosciences based?
CardiaTec Biosciences is headquartered in Cambridge, United Kingdom, in the Europe region.
How does CardiaTec Biosciences make money?
One revenue line is on record: drug Target Discovery & Licensing.
Who are CardiaTec Biosciences's main competitors?
Broad incumbents on record are Isomorphic Labs and Recursion Pharmaceuticals. Direct peers are Iambic Therapeutics, Insitro, Exscientia and BenevolentAI. Emerging players are Standigm, Owkin, Tenaya Therapeutics and Cardior Pharmaceuticals.
Does CardiaTec Biosciences have an API?
No public API is recorded for CardiaTec Biosciences.
What industry is CardiaTec Biosciences in?
CardiaTec Biosciences's product category is AI-driven Cardiovascular Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.